van den Broek Richard 4

What Happened
Richard van den Broek, a director of Pulse Biosciences (PLSE), received derivative awards (reported as "A" = grant/award) on June 11, 2026 covering 30,000 and 8,423 shares (total 38,423). The Form 4 lists an acquisition price of $0.00 for each award (common for option grants reported as derivatives). These are option awards that will vest over time rather than an immediate purchase of common stock.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-15 (filing appears timely).
• Reported acquisition price: $0.00 (derivative awards).
• Grants: 30,000-share award (footnote F1) and 8,423-share award (footnote F2) — total 38,423.
• Vesting (per footnotes):
  • F1 (30,000): vests in equal monthly installments over one year, first vesting on July 11, 2026.
  • F2 (8,423): vests in equal quarterly installments over one year, first vesting on September 5, 2026.
• Shares owned after transaction: not specified in the provided data.
• Transaction type: derivative option grants (not exercises or open-market purchases/sales).

Context
These awards are compensation/retention-type option grants that vest over time and thus do not represent immediate insider buying or selling. Options must vest (and, if applicable, be exercised) before they convert into actual shares; the Form 4 shows the grant but no exercise or sale. For retail investors, grant activity signals company compensation actions but should not be taken alone as a directional market indicator.